Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial.
Wataru ShimizuYoshiaki KubotaYu HoshikaKosuke MozawaShuhei TaraYukichi TokitaKenji YodogawaYu-Ki IwasakiTakeshi YamamotoHitoshi TakanoYayoi TsukadaKuniya AsaiMasaaki MiyamotoYasushi MiyauchiEitaro KodaniMasahiro IshikawaMitsunori MaruyamaMichio OganoJun Tanabenull nullPublished in: Cardiovascular diabetology (2020)
The EMBODY trial was registered by the UMIN in November 2017 (ID: 000030158). UMIN000030158; https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034442 .
Keyphrases
- acute myocardial infarction
- phase iii
- end stage renal disease
- study protocol
- clinical trial
- chronic kidney disease
- ejection fraction
- phase ii
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- randomized controlled trial
- percutaneous coronary intervention
- minimally invasive
- open label
- patient reported outcomes
- coronary artery disease
- placebo controlled